Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 2 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

Audrey Abella, 6 days ago
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Standard ART plus maraviroc does not improve outcomes in treatment-naïve HIV patients

18 Mar 2020

Adding maraviroc to standard combined antiretroviral therapy (c-ART), which consists of three or more ART drugs, does not result in better clinical outcomes among patients initiating treatment for advanced HIV infection, reveals a study.

A total of 409 HIV-positive, antiretroviral-naïve adults with CD4 counts <0.200 × 109 cells/L and/or a previous AIDS-defining event (ADE) were enrolled in this randomized controlled trial to assess the benefit of adding maraviroc to standard c-ART.

Of the participants, 202 were assigned to maraviroc and 207 to placebo. Participants received c-ART plus placebo or maraviroc (300 mg twice daily with dose modification) for 72 weeks.

During follow-up, the primary endpoint of first occurrence of severe morbidity (ie, new ADE, selected serious infections, serious non-ADE, immune reconstitution inflammatory syndrome or death) was comparable between the two treatment groups (11.1 vs 11.2 person-years in the maraviroc and placebo groups, respectively; hazard ratio, 0.97, 95 percent confidence interval [CI], 0.57–1.67).

In addition, the incidence of adverse events grade 2 was 36.1 vs 41.5 per 100 person-years (incidence rate ratio, 0.87, 95 percent CI, 0.65–1.15), respectively.

Certain limitations have to considered. First, 64 patients discontinued treatment during follow-up. Second, the study was not powered to assess time-dependent outcomes or effect modification.

“Patients diagnosed with advanced HIV infection have a poor prognosis despite initiation of c-ART,” the investigators said.

Maraviroc is an ART with immunologic effects, they noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 2 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 

Audrey Abella, 6 days ago
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.